NunaBio is thrilled to announce the recent appointment of their new Chief Operating Officer Sarah Greenhalgh and Technical Lead for Synthetic Biology, Dr Rachel Telfer-Sutherland.
Sarah’s background in supporting academic, clinical and commercial research projects and clinical trials is particularly valuable for NunaBio as they strive to provide high-quality DNA synthesis products and services to support the advancement of science and medicine. She has a track record of success having implemented efficient operations and optimized processes to deliver results that exceed expectations.
“I have joined the company at an exciting time, and have enjoyed supporting the team to ensure that NunaBio is best placed to achieve its ambitious goals.”
“I am thrilled to have recently joined the incredibly talented team at NunaBio. I have already learnt a huge amount from the team and look forward to helping with the development of their novel DNA synthetic strategies.”
Rachel’s biology specialism is underpinned by doctoral research in breast cancer genetics followed by commercial R&D experience in the development of new diagnostic tests. She will be involved in designing and testing new methods for synthesizing DNA using our innovative patented technology.
These two new posts complement the existing interdisciplinary team of talented scientists bringing fresh perspectives, expertise, and ideas to the company’s DNA synthesis efforts.
NunaBio is at a critical time in its evolution as a company, and is excited to have such a talented and experienced team to support the journey. We look forward to seeing the positive impact that these new appointments will have on the science, operations, growth, and success.
We are looking to broaden the NunaBio team and have opportunities in both our scientific and commercial teams. Please visit the Careers section of our webpage to view our current vacancies, or submit your CV and covering letter explaining why you’d like to join our team to firstname.lastname@example.org.
NunaBio is a privately owned life sciences company based in the northeast of the UK.
Founded in 2021, our multi-patented technology can quickly produce large quantities of pure synthetic DNA using environmentally conscious processes.
NunaBio’ platform enables the synthesis of whole genes and DNA fragments of unprecedented length without the use of plasmids or primers, which are existing bottlenecks in the synthetic biology industry. Our technology has broad applications across multiple areas of life sciences, including gene therapy, T cell engineering, viral vector synthesis, hybridisation capture and targeted biomarker panels.
Our mission is to enable game changing technologies across the life sciences and biotech sectors by providing novel high-quality material at scale – we are not only making products, we are empowering the most cutting-edge technologies to make an impact on the world.